Meeting
2019 ASCO Annual Meeting
TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Authors
Camillo Porta
Department of Internal Medicine, University of Pavia and Division of Traslational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy
Camillo Porta , Elena Verzoni , Bernard Escudier , Sumanta K. Pal , Michael B. Atkins , Thomas E. Hutson , Michael N. Needle , David F. McDermott , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02627963
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4572)
DOI
10.1200/JCO.2019.37.15_suppl.4572
Abstract #
4572
Poster Bd #
398
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian I. Rini
Poster
2023 ASCO Genitourinary Cancers Symposium
The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups and correlates with gut microbiota (GM) in patients with advanced renal cell carcinoma (RCC).
First Author: Carolina Alves Costa Silva
Poster
2021 Genitourinary Cancers Symposium
Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.
First Author: Michael Szarek
Poster
2020 ASCO Virtual Scientific Program
Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.
First Author: Mridula Krishnan